The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.86BCNY
578.65M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue (TTM)
793.05MCNY
118.94M · vs all stocks (USD)
Updated Oct 24, 2026
Profit Margin
-4.21%
vs Medical Devices peers
Updated Oct 24, 2026
Beta
-0.3390x
vs all stocks
Updated Oct 24, 2026
52-Week Change
-41.79%
vs all stocks
Updated Oct 24, 2026
Market Capitalization
3.86BCNY
578.65M · vs all stocks (USD)
Updated Oct 24, 2026
Enterprise Value
3.51BCNY
526.89M · vs all stocks (USD)
Updated Oct 24, 2026
Forward P/E
41.14x
vs Medical Devices peers
Updated Oct 24, 2026
Price to Sales (TTM)
4.30x
vs Medical Devices peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 4.86×.Updated Oct 24, 2026
Price to Book (MRQ)
2.79x
vs Medical Devices peers
Updated Oct 24, 2026
Enterprise to Revenue
4.43x
vs Medical Devices peers
Updated Oct 24, 2026
Gross Margin
56.34%
vs Medical Devices peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 62.21%.Updated Oct 24, 2026
Profit Margin
-4.21%
vs Medical Devices peers
Updated Oct 24, 2026
Operating Margin
-50.41%
vs Medical Devices peers
Updated Oct 24, 2026
Return on Assets (TTM)
-1.93%
vs Medical Devices peers
Updated Oct 24, 2026
Return on Equity (TTM)
-2.64%
vs Medical Devices peers
Updated Oct 24, 2026
Revenue (TTM)
793.05MCNY
118.94M · vs all stocks (USD)
Updated Oct 24, 2026
Revenue per Share (TTM)
6.28CNYUpdated Oct 24, 2026
Quarterly Revenue Growth
4.00%
vs Medical Devices peers
Updated Oct 24, 2026
Gross Profit (TTM)
493.33MCNY
73.99M · vs all stocks (USD)
Updated Oct 24, 2026
EBITDA (TTM)
118.11MCNY
17.71M · vs all stocks (USD)
Updated Oct 24, 2026
Net Income (TTM)
-33.40MCNY
-5.01M · vs all stocks (USD)
Updated Oct 24, 2026
Quarterly Earnings Growth (YoY)
3.96%
vs Medical Devices peers
Updated Oct 24, 2026
Operating Cash Flow (TTM)
-2.47MCNY
-369.73K · vs all stocks (USD)
Updated Oct 24, 2026
Levered Free Cash Flow (TTM)
-25.18MCNY
-3.78M · vs all stocks (USD)
Updated Oct 24, 2026
Payout Ratio
66.67%
vs Medical Devices peers
Updated Oct 24, 2026
Minority Interest (Equity)
13.56MCNYFY2025 · Dec 31, 2025
Revenue
773.87MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
269.00MCNYFY2025 · Dec 31, 2025
Gross Profit
504.86MCNYFY2025 · Dec 31, 2025
Operating Income
42.04MCNY
6.30M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
117.12KCNYFY2025 · Dec 31, 2025
Income Tax Expense
-10.47MCNYFY2025 · Dec 31, 2025
Net Income
10.59MCNYFY2025 · Dec 31, 2025
EBIT
7.04MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
118.11MCNYFY2025 · Dec 31, 2025
Research & Development
147.01MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
113.88MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
19.02MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
3.03MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
6.92MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
127.24MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
127.24MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
10.59MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
865.75KCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-115.00MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-245.12MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
338.58MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
10.59MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
17.82MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-116.03MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-27.37MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-130.13MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-846.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
924.29MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-51.84MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
405.18MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-179.45MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-16.58MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-52.07MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
157.08MCNYFY2025 · Dec 31, 2025
Shares Outstanding
134.67MSharesUpdated Oct 24, 2026
Float Shares
87.57MSharesUpdated Oct 24, 2026
% Held by Insiders
32.85%
vs all stocks
Updated Oct 24, 2026
% Held by Institutions
20.30%
vs all stocks
Updated Oct 24, 2026
Total Cash (MRQ)
355.19MCNY
53.27M · vs all stocks (USD)
Updated Oct 24, 2026
Total Cash per Share (MRQ)
2.64CNYUpdated Oct 24, 2026
Total Debt (MRQ)
409.04MCNY
61.35M · vs all stocks (USD)
Updated Oct 24, 2026
Total Debt to Equity (MRQ)
0.3306x
vs Medical Devices peers
Updated Oct 24, 2026
Current Ratio (MRQ)
1.75x
vs Medical Devices peers
Updated Oct 24, 2026
Book Value per Share (MRQ)
9.08CNYUpdated Oct 24, 2026
Total Assets
2.00BCNY
299.48M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.09BCNYFY2025 · Dec 31, 2025
Total Liabilities
670.42MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
902.23MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
120.74MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
549.68MCNYFY2025 · Dec 31, 2025
Cash
339.57MCNYFY2025 · Dec 31, 2025
Cash Equivalents
2.30MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
341.86MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
50.01MCNYFY2025 · Dec 31, 2025
Accounts Receivable
431.62MCNYFY2025 · Dec 31, 2025
Inventory
229.37MCNYFY2025 · Dec 31, 2025
Accounts Payable
164.83MCNYFY2025 · Dec 31, 2025
Short-term Debt
300.64MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
400.93KCNYFY2025 · Dec 31, 2025
Long-term Debt
39.61MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
42.40MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
134.67MCNYFY2025 · Dec 31, 2025
Retained Earnings
141.11MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.33BCNY
198.93M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
40.02MCNYFY2025 · Dec 31, 2025
52-Week Low
24.46CNYUpdated Oct 24, 2026
52-Week High
51.99CNYUpdated Oct 24, 2026
52-Week Change
-41.79%
vs all stocks
Updated Oct 24, 2026
Beta
-0.3390x
vs all stocks
Updated Oct 24, 2026
50-Day MA
28.33CNYUpdated Oct 24, 2026
200-Day MA
33.56CNYUpdated Oct 24, 2026
Avg 10-Day Volume
1.35MSharesUpdated Oct 24, 2026
Avg 30-Day Volume
1.80MSharesUpdated Oct 24, 2026
Diluted EPS (TTM)
-0.2500CNYUpdated Oct 24, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable